Riskpilot← Back to searchSign inGet full accessRLK-Pharma Oy
OYDissolvedY-tunnus 2800399-1Männistönkatu 3-B84Retail sale of medical and orthopaedic goods · NACE 4774Est. 2016— employees
Revenue 2025
EUR 0
EBITDA margin
—
-126% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
EUR -8K
-124% vs 2024
| Revenue | EUR 0 | — |
| EBITDA | EUR -8K | -126% |
| Net profit | EUR -8K | -124% |
| Total assets | EUR 521K | -10% |
| Equity | EUR 521K | -9% |
| Employees | — | — |
Legal name
RLK-Pharma Oy
Y-tunnus number
2800399-1
Legal form
Osakeyhtiö
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
12. joulukuuta 2016
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Yhtiön toimialana on lääketieteellisten ja terveydenhoitoon liittyvien tuotteiden ja tarvikkeiden, kemikalio-, rohdos- ja luontaistuotteiden ja kosmetiikan vähittäis- ja tukkumyynti, tuonti, vienti ja valmistus ja lisäksi työvoiman sekä koneiden, laitteiden, kalusteiden, asuin- ja liikekiinteistöjen sekä huoneistojen vuokraus. Yhtiön toimialaan kuuluu lääke- ja apteekkialaan liittyvä konsultointi, tuotekehitys ja markkinointipalvelujen myynti. Yhtiö voi myös omistaa ja hallita arvopapereita, kiinteää ja irtainta omaisuutta, ostaa ja myydä arvopapereita, ostaa ja myydä asunto- ja kiinteistöyhtiön osakkeita sekä asuin-ja liikekiinteistöjä.
Address
Männistönkatu 3-B84
Phone
+3580505051160
Email
raija.kaitila@apteekit.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 481 | 601 | 568 | 561 | 574 | 123 | 0 |
| Staff expenses | — | — | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 112 | 142 | 149 | 155 | 150 | 29 | −8 |
| Depreciation & amort. | — | — | −9 | −6 | −5 | −4 | −3 |
| EBIT | 112 | 142 | 141 | 149 | 145 | 26 | −10 |
| Net financials | — | 0 | −0 | 1 | 1 | 14 | 3 |
| Profit before tax | 112 | 142 | 141 | 150 | 146 | 40 | −8 |
| Tax | 22 | 28 | 28 | 30 | 29 | 8 | −0 |
| Net profit | 89 | 114 | 113 | 120 | 117 | 32 | −8 |
| Item | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 195 | 369 | 451 | 548 | 611 | 576 | 521 |
| Equity | 150 | 344 | 429 | 515 | 590 | 575 | 521 |
| Long-term debt | — | — | — | — | 0 | 0 | 0 |
| Short-term debt | 44 | 25 | 22 | 33 | 21 | 1 | 0 |
| Total debt | 44 | 25 | 22 | 33 | 21 | 1 | 0 |
EBITDA margin
-766600.0%
This company
15.8%
Market median
-4851999% vs market
20182025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20182025
Return on equity
-1.5%
This company
18.4%
Market median
-108% vs market
20182025
Net profit margin
-762500.0%
This company
8.1%
Market median
-9413680% vs market
20182025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20182025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2018Filed via PRH / YTJ · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KA Deputy Member | Deputy Member | 2016 | — | — |
SR | Audit | 2020 | — | — |
TE Deputy auditor | Deputy auditor | 2020 | — | — |
RK Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RLK-Pharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katri Annina Kaitila | Deputy Member | 0 companies |
| Stefan Rolf Axel Wiklund | Audit | 0 companies |
| Tony Erik Hämäläinen | Deputy auditor | 0 companies |
| Raija-Liisa Kaitila | Chief Executive Officer | 0 companies |